戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d cancer that was refractory to radioiodine (iodine-131).
2        The patient also underwent whole-body iodine 131 ((131)I) scintigraphy.
3  ((125)I)-labeled FIAU was used in vitro and iodine 131 ((131)I)-labeled FIAU, in vivo.
4 estimate the maximum tolerated dose (MTD) of iodine 131 ((131)I)-tositumomab (anti-CD20 antibody) tha
5 n-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I).
6 prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated
7 d recombinant human TSH [rhTSH]) and the two iodine-131 ((131)I) activities (1.1 or 3.7 GBq).
8 sustained intratumoral (i.t.) delivery of an iodine-131 ((131)I) radionuclide and a CpG oligodeoxynuc
9 ents exposed to radioactive iodines, chiefly iodine-131 ((131)I), after the 1986 Chornobyl (Ukrainian
10 ast one measurement of occult/minimal tumor (iodine 131[(131)I]-3F8 imaging, marrow immunocytology, o
11 of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with adva
12 proximately 740,000 Ci (2.73 x 10(16) Bq) of iodine 131 (131I) were released to the atmosphere from t
13 hnetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodies (all direc
14 ion tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In
15             Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted t
16 sure to low or moderate doses of radioactive iodine-131 (131I) at a young age is a public health conc
17 0 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma wh
18 trahematopoietic toxicity was conducted with iodine-131 (131I) labeled monoclonal antibody (MAb) CC49
19  by a single dose of the therapeutic isotope iodine-131 (131I) without evidence of recurrence up to 5
20                                              Iodine-131 anti-B1 antibody radioimmunotherapy for B-cel
21 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous s
22 ease, thyroid eye disease and treatment with iodine-131, antithyroid drug treatment, treatment of hyp
23  cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis.
24                                              Iodine-131-FIBG is an analog of MIBG with prolonged bind
25 onths between a low administered radioactive iodine ((131)I) dose (1.1 GBq) and the standard high dos
26                       The use of radioactive iodine ((131)I) for the treatment of thyroid carcinoma h
27 ancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeuti
28 ies reporting the performance of radioactive iodine ((131)I) therapy in differentiated thyroid cancer
29                                  Radioactive iodine ((131)I) therapy may be used to treat thyroid can
30 unding regions, particularly for radioactive iodine ((131)I)-exposed children.
31                    Patients with radioactive iodine ((131)I)-refractory locally advanced or metastati
32 e beta-particle emissions of the radioactive iodine ((131)I).
33      A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce freque
34 py-relapsed/refractory patients treated with iodine (131)I tositumomab in a phase I/II single-center
35                                              Iodine-131 images were quantitated and used for pharmaco
36                                    High-dose iodine 131 is the treatment of choice in the United Stat
37                                              Iodine-131 is preferred by many investigators over other
38 postoperative administration of radioiodine (iodine-131) is controversial in the absence of demonstra
39                                              Iodine-131-IUdR was used as a tracer for imaging and qua
40                                              Iodine-131-labeled anti-CD45 antibody has been added to
41 okinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) ta
42 aging evaluation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone sca
43                                              Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has bee
44                                              Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) provide
45                                              Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) selecti
46  2 to 4 months included computed tomography, iodine-131-metaiodobenzylguanidine (131)I-MIBG; through
47 prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment
48 odine-124 PET study indicated that a dose of iodine-131 of 2000 cGy or more could be delivered to the
49 and treatment (targeted radionuclide therapy/iodine-131) of melanoma.
50 astin-like polypeptide (ELP) conjugated with iodine-131 radionuclides ((131)I-ELP) when combined with
51 or without lenalidomide, in the treatment of iodine 131-refractory DTC.
52 al and the response rate among patients with iodine-131-refractory thyroid cancer.
53                         Due to the amount of iodine 131 released in nuclear tests and its active upta
54 a, attributable to the very large amounts of iodine 131 released, was first noticed in children with
55 timulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed.
56        The patient also underwent whole-body iodine 131 scintigraphy (Fig 5).
57                                              Iodine-131 scintigraphy for differentiated thyroid carci
58 ivity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iodide were generated.
59 ollicular thyroid cancer after postoperative iodine-131 therapy.
60 psed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day
61 HL were treated in a phase I trial combining iodine-131 tositumomab (ranging from 0.30 to 0.75 Gy tot
62              A follow-up phase II trial with iodine-131 tositumomab at the dose of 0.75 Gy TBD with B
63 t resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administr
64 ficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with chemotherapy-rel
65  the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refr
66                                              Iodine-131 tositumomab produced a high overall response
67                          The tositumomab and iodine-131 tositumomab therapeutic regimen produces high
68 ded toxicities apparent with the addition of iodine-131 tositumomab up to a dose of 0.75 Gy TBD to hi
69 apy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008.
70         Patients received a single course of iodine-131 tositumomab.
71                                              Iodine-131 uptake in the anterior mediastinum in patient
72                                Postoperative iodine-131 was given to 85.4% of patients with papillary
73                                              Iodine-131 was measured in Potomac River water and sedim
74 essive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive